Search
Selected Filter
Filter Results
Displaying 331–340 of 541 news results
-
Dec 17, 2019
First Human Study in US for Induced Pluripotent Stem Cells to be Launched for Advanced Dry AMD
Research NewsCurrently there are no treatments for Advanced Dry AMD, also known as GA, which can lead to significant central vision loss
-
Dec 16, 2019
First Patient Receives ProQR’s AON Therapy in Clinical Trial for RP Caused by RHO-P23H Mutation
Research NewsThe trial becomes ProQR’s third human study for inherited retinal disease therapies
-
Dec 11, 2019
Families and Scientists Meet to Discuss Therapy Development for People with RDH12 Mutations
Research NewsProof-of-concept for RDH12 gene therapy demonstrated in mouse model
-
Dec 6, 2019
Offer support to patients with inherited eye diseases
In the PressWhile genetic testing can direct treatment and identify those at risk, it is important to have support available when patients test positive.
-
Dec 6, 2019
Returning the favor: Never too late to give back as a premium surgeon
In the PressWhether local or international, through donation of services or funds, there is a way for everyone to give back.
-
Nov 27, 2019
Foundation NewsKnown as Pro-EYS, the study will help researchers design clinical trials for potential therapies
-
Nov 15, 2019
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Research NewsPhase 1/2a human study will evaluate neural progenitors for preserving vision
-
Nov 7, 2019
AGTC Announces Development of Stargardt Disease Gene Therapy
Research NewsDual-vector delivery system designed to deliver the large ABCA4 gene
-
Oct 29, 2019
Iveric Bio’s Therapy Slows Retinal Degeneration in Phase 2b Trial for Dry AMD
Research NewsZimura inhibits a complement protein known as C5, a component of the immune system that, when overactive, can cause retinal degeneration.
-
Oct 18, 2019
ReNeuron Reports Interim Results for Eight Patients with RP in Phase 2a Trial for Stem Cell Therapy
Research NewsThe Foundation funded earlier lab studies that made the clinical trial possible.